Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

EML4-ALK: honing in on a new target in non-small-cell lung cancer.

Horn L, Pao W.

J Clin Oncol. 2009 Sep 10;27(26):4232-5. doi: 10.1200/JCO.2009.23.6661. Epub 2009 Aug 10. No abstract available.

PMID:
19667260
2.

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, Settleman J, Kobayashi S, Mark EJ, Rodig SJ, Chirieac LR, Kwak EL, Lynch TJ, Iafrate AJ.

J Clin Oncol. 2009 Sep 10;27(26):4247-53. doi: 10.1200/JCO.2009.22.6993. Epub 2009 Aug 10.

3.

EML4-ALK rearrangement and its clinical significance in Chinese patients with advanced non-small cell lung cancer.

Wang Z, Zhang X, Bai H, Zhao J, Zhuo M, An T, Duan J, Yang L, Wu M, Wang S, Wang Y, Wu Y, Wang J.

Oncology. 2012;83(5):248-56. doi: 10.1159/000341381. Epub 2012 Sep 4.

PMID:
22964709
4.

Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation.

Miyanaga A, Shimizu K, Noro R, Seike M, Kitamura K, Kosaihira S, Minegishi Y, Shukuya T, Yoshimura A, Kawamoto M, Tsuchiya S, Hagiwara K, Soda M, Takeuchi K, Yamamoto N, Mano H, Ishikawa Y, Gemma A.

BMC Cancer. 2013 May 29;13:262. doi: 10.1186/1471-2407-13-262.

5.

A survey of Japanese thoracic oncologists' perception of diagnostic and treatment strategies for EGFR mutant or EML4-ALK fusion non-small cell lung cancer.

Hotta K, Kiura K, Tabata M, Takigawa N, Tanimoto M, Ueoka H.

Chest. 2014 Dec;146(6):e222-e225. doi: 10.1378/chest.14-2055. No abstract available.

PMID:
25451370
6.

Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy.

Takeda M, Okamoto I, Sakai K, Kawakami H, Nishio K, Nakagawa K.

Ann Oncol. 2012 Nov;23(11):2931-6. doi: 10.1093/annonc/mds124. Epub 2012 Jul 5.

PMID:
22771825
7.

Variations in molecular profile in NSCLC can be analyzed using cytological samples: development of EGFR resistance mutations and coexistence of ALK-EML4 translocation in an EGFR-sensitive patient.

Lozano MD, Labiano T, Zudaire I, Subtil JC, Gúrpide A, Echeveste JI, Zulueta JJ, Martín-Algarra S, Pérez-Gracia JL.

Int J Surg Pathol. 2015 Apr;23(2):111-5. doi: 10.1177/1066896914539551. Epub 2014 Jun 17.

PMID:
24942894
8.

Detection of EML4-ALK fusion genes in a few cancer cells from transbronchial cytological specimens utilizing immediate cytology during bronchoscopy.

Kanaji N, Bandoh S, Ishii T, Tadokoro A, Watanabe N, Takahama T, Haba R, Imataki O, Dobashi H, Matsunaga T.

Lung Cancer. 2012 Aug;77(2):293-8. doi: 10.1016/j.lungcan.2012.03.018. Epub 2012 Apr 10.

PMID:
22494566
9.

Non-small cell lung cancer patients with EML4-ALK fusion gene are insensitive to cytotoxic chemotherapy.

Morodomi Y, Takenoyama M, Inamasu E, Toyozawa R, Kojo M, Toyokawa G, Shiraishi Y, Takenaka T, Hirai F, Yamaguchi M, Taguchi K, Seto T, Sugio K, Ichinose Y.

Anticancer Res. 2014 Jul;34(7):3825-30.

PMID:
24982409
10.

[Research progress in non-small cell lung cancer with concomitant EML4-ALK fusion gene and EGFR gene mutation].

Zeng Z, Wu Y.

Zhongguo Fei Ai Za Zhi. 2011 Nov;14(11):880-4. doi: 10.3779/j.issn.1009-3419.2011.11.09. Review. Chinese.

11.
13.

The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.

Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, Cheng LC, Ho KK, Au JS, Chung LP, Pik Wong M; University of Hong Kong Lung Cancer Study Group.

Cancer. 2009 Apr 15;115(8):1723-33. doi: 10.1002/cncr.24181.

14.

EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations.

Tiseo M, Gelsomino F, Boggiani D, Bortesi B, Bartolotti M, Bozzetti C, Sammarelli G, Thai E, Ardizzoni A.

Lung Cancer. 2011 Feb;71(2):241-3. doi: 10.1016/j.lungcan.2010.11.014. Epub 2010 Dec 18.

PMID:
21168933
15.

[What choice of first-line treatment?].

Moro-Sibilot D.

Rev Pneumol Clin. 2011 Jun;67 Suppl 1:S20-3. doi: 10.1016/S0761-8417(11)70006-2. French.

PMID:
21777762
16.

Reflex testing for epidermal growth factor receptor mutation and anaplastic lymphoma kinase fluorescence in situ hybridization in non-small cell lung cancer.

Mino-Kenudson M, Mark EJ.

Arch Pathol Lab Med. 2011 May;135(5):655-64. doi: 10.1043/2011-0029-RAI.1. Review.

PMID:
21526964
17.

The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.

Normant E, Paez G, West KA, Lim AR, Slocum KL, Tunkey C, McDougall J, Wylie AA, Robison K, Caliri K, Palombella VJ, Fritz CC.

Oncogene. 2011 Jun 2;30(22):2581-6. doi: 10.1038/onc.2010.625. Epub 2011 Jan 24.

PMID:
21258415
18.

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H.

Nature. 2007 Aug 2;448(7153):561-6. Epub 2007 Jul 11.

PMID:
17625570
19.

Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene.

Chiari R, Duranti S, Ludovini V, Bellezza G, Pireddu A, Minotti V, Bennati C, Crinò L.

J Clin Oncol. 2014 Mar 20;32(9):e30-2. doi: 10.1200/JCO.2012.47.7141. Epub 2014 Jan 13. No abstract available.

PMID:
24419120
20.

EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas.

Shinmura K, Kageyama S, Tao H, Bunai T, Suzuki M, Kamo T, Takamochi K, Suzuki K, Tanahashi M, Niwa H, Ogawa H, Sugimura H.

Lung Cancer. 2008 Aug;61(2):163-9. doi: 10.1016/j.lungcan.2007.12.013. Epub 2008 Feb 1.

PMID:
18242762

Supplemental Content

Support Center